The US Food and Drug Administration (FDA) has awarded medical device start-up Opticyte for its Cell O2 Patient Monitor that provides real-time, continuous monitoring of patients at risk of organ failure.
Awarded Breakthrough Device Designation, the Cell O2 Patient Monitor uses non-invasive optical spectroscopy technology to measure and detect systemic low oxygen levels inside cells.
It is hoped the device will reduce organ failure through immediate and continuous monitoring of cellular oxygen levels during hospitalisation for sepsis, trauma and myocardial infarction.
Lori Arakaki, Ph.D., Opticyte co-founder and CEO, said the designation will allow Opticyte to quickly reach sepsis, trauma, and cardiac surgery patients with organ dysfunction who are on the verge of organ failure.
... to continue reading you must be subscribed